PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Narsoplimab→

Narsoplimab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2108782-45-0
Molecular formula
C6340H9876N1680O1996S48
Molecular weight
143109.39 g/mol
Drug class
Mannan-binding lectin-associated serine protease 2 (MASP-2) inhibitorcomplement pathway monoclonal antibody
Mechanism of action
Inhibits MASP-2, the effector enzyme of the lectin pathway of complement, blocking lectin-dependent activation of complement components C3 and C4 without inhibiting the classical or alternative complement pathways.
Indications / reported uses
  • Treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and paediatric patients aged 2 years and older under the US YARTEMLEA indication (approved 23 December 2025)

Sources: NLM DailyMed — YARTEMLEA (narsoplimab-wuug), updated 20 January 2026 · FDA Drug Trials Snapshot — YARTEMLEA · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Narsoplimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Narsoplimab Permitted Daily Exposure (PDE) report (the Narsoplimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Narsoplimab Occupational Exposure Limit (OEL) report (the Narsoplimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.